Cue Biopharma, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M | $3.2M | $3.5M | $1.1M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $37.7M | $36.3M | $40.8M | $38.6M | $41.3M | $33.5M | $27.5M | $28.5M |
| SG&A Expense | $16.2M | $14.6M | $16.7M | $16.2M | $17.3M | $14.7M | $12.7M | $11.3M |
| Operating Income | $-26.6M | $-41.5M | $-52.1M | $-53.2M | $-43.7M | $-45.0M | $-36.8M | $-38.7M |
| Operating Margin | -96.7% | -446.9% | -949.9% | -4,275.1% | -292.6% | -1,428.0% | -1,063.2% | -3,386.7% |
| Interest Expense | $100.0K | $100.0K | $100.0K | $109.0K | — | — | — | — |
| Pretax Income | — | — | — | $-53.0M | $-43.7M | $-44.6M | $-36.3M | $-38.2M |
| Income Tax Expense | $500.0K | $0 | — | $0 | $495.0K | $206.3K | $412.5K | $825.0K |
| Net Income | $-26.6M | $-40.7M | $-50.7M | $-53.0M | $-44.2M | $-44.8M | $-36.7M | $-39.0M |
| Net Margin | -96.9% | -438.0% | -924.1% | -4,257.8% | -295.6% | -1,419.8% | -1,061.2% | -3,411.5% |
| EPS (Basic) | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 | $-1.56 | $-1.66 | $-1.94 |
| EPS (Diluted) | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 | $-1.56 | $-1.66 | $-1.94 |
| Shares Outstanding (Basic) | 94.7M | 56.3M | 45.8M | 35.6M | 31.3M | 30.4M | 26.6M | 20.7M |
| Shares Outstanding (Diluted) | 94.7M | 56.3M | 45.8M | 35.6M | 31.3M | 30.4M | 26.6M | 20.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |